^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | COTI-2 (p53 stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting mutant p53 with COTI-2: A new approach for the treatment of patients with triple-negative breast cancer?
Published date:
05/16/2018
Excerpt:
The aim of this study was to investigate COTI-2 as a new treatment for TNBC...COTI-2 binding to mutant p53 was obtained using SPR...Highly synergistic growth inhibition, i.e. CI < 1, was found when COTI-2 was combined with doxorubicin in 6 different cell lines. In addition, docetaxel plus COTI-2 was synergistic in 4/6 cell lines, carboplatin plus COTI-2 was synergistic in 3/6, while cisplatin plus COTI-2 was synergistic in 2/6 cell lines...conclude that targeting mutant p53 with COTI-2 is a potential approach for treating p53-mutated TNBC...
Secondary therapy:
carboplatin; cisplatin; docetaxel; doxorubicin hydrochloride
DOI:
10.1200/JCO.2018.36.15_suppl.e13121
